BackIonis Pharmaceuticals Overview

Ionis Pharmaceuticals Total Current Liabilities

Latest total current liabilities for IONS: $1.2B.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$1.19B

Peer trimmed avg / median

Loading

Ionis Pharmaceuticals Total Current Liabilities History

Loading

Ionis Pharmaceuticals vs. peers: Total Current Liabilities Comparison

Loading

Ionis Pharmaceuticals Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ionis Pharmaceuticals (IONS) FAQ

Ionis Pharmaceuticals (IONS) currently reports a total current liabilities of $1.2B as of September 2026. Use the charts on this page to explore Ionis Pharmaceuticals's total current liabilities history and peer comparisons.

Ionis Pharmaceuticals reported $1.2B in total current liabilities as of September 2026. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $1.2B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ionis Pharmaceuticals, and consider following IONS for alerts when major investors trade the stock.

Ionis Pharmaceuticals is classified in the Healthcare sector. On total current liabilities, it currently shows $1.2B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IONS with unrelated industries.